This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2006 Mar;52(3):319-21.

Does low-dose ASA help prevent cardiovascular events in women?

Abdullah Alkhenizan¹, W Farooq

Affiliations

PMID: 16572576
PMCID: PMC1479715

Does low-dose ASA help prevent cardiovascular events in women?

Abdullah Alkhenizan et al. Can Fam Physician. 2006 Mar.

. 2006 Mar;52(3):319-21.

Authors

Abdullah Alkhenizan¹, W Farooq

Affiliation

¹ Department of Family Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

PMID: 16572576
PMCID: PMC1479715

No abstract available

PubMed Disclaimer

Similar articles

The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk.
Pratt S, Thompson VJ, Elkin EP, Næsdal J, Sörstadius E. Pratt S, et al. Am J Cardiovasc Drugs. 2010;10(5):281-8. doi: 10.2165/11584410-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20666569
Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation.
Cea Soriano L, Bueno H, Lanas A, García Rodríguez LA. Cea Soriano L, et al. Thromb Haemost. 2013 Dec;110(6):1298-304. doi: 10.1160/TH13-04-0326. Epub 2013 Sep 5. Thromb Haemost. 2013. PMID: 24008261
Chronotherapy with low-dose aspirin for prevention of complications in pregnancy.
Ayala DE, Ucieda R, Hermida RC. Ayala DE, et al. Chronobiol Int. 2013 Mar;30(1-2):260-79. doi: 10.3109/07420528.2012.717455. Epub 2012 Sep 24. Chronobiol Int. 2013. PMID: 23004922 Clinical Trial.
Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation.
Herlitz J, Tóth PP, Naesdal J. Herlitz J, et al. Am J Cardiovasc Drugs. 2010;10(2):125-41. doi: 10.2165/11318440-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20334450 Review.
Drug delivery and therapeutic impact of extended-release acetylsalicylic acid.
Bliden KP, Patrick J, Pennell AT, Tantry US, Gurbel PA. Bliden KP, et al. Future Cardiol. 2016 Jan;12(1):45-58. doi: 10.2217/fca.15.60. Epub 2015 Sep 10. Future Cardiol. 2016. PMID: 26356085 Review.

See all similar articles

References

1. Heart and Stroke Foundation of Canada. The changing face of heart disease and stroke in Canada. Toronto, Ont: Heart and Stroke Foundation of Canada; 2000. pp. 68–69.
1. Nelson CR, Knapp DE. Medication therapy in ambulatory medical care. National ambulatory medical care survey and national hospital ambulatory medical care survey, 1992. National Center for Health Statistics. Adv Data. 1997;290(8):1–24. - PubMed
1. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U. S. Preventive Services Task Force. Ann Intern Med. pp. 161–172. - PubMed
1. Alkhenizan A. Should patients who have not had a cardiac event take ASA to prevent one? Can Fam Physician. 2002;48:55–57. - PMC - PubMed
1. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. pp. 166–181. - PubMed

LinkOut - more resources

Full Text Sources